Finance

Lists
Outlook: 15.4% bullish·30.8% bearish
Go to analysis
AQST:NASDAQ
Aquestive Therapeutics Inc
$3.61
-1.37%
(-0.050) 1D
$3.60
-0.28% (-0.0100)
After hours
Closed: Nov 6, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AQST...
Open
$3.71
High
$3.76
Low
$3.55
Mkt. cap
453.73M
Avg. vol.
2.18M
Volume
4.14M
52-wk high
$6.74
52-wk low
$2.93
EPS
-$0.64
Beta
1.49
Shares outstanding
125.69M
No. of employees
147
Open
$3.71
High
$3.76
Low
$3.55
Mkt. cap
453.73M
Avg. vol.
2.18M
Volume
4.14M
52-wk high
$6.74
52-wk low
$2.93
EPS
-$0.64
Beta
1.49
Shares outstanding
125.69M
No. of employees
147
News stories
From web sources and news partners
About Aquestive Therapeutics Inc
CEO-
Employees147
Founded2004
HeadquartersWarren, New Jersey, United States
SectorHealth Care
IndustryPharmaceutical industry
Websiteaquestive.com
Analyst ratings
Based on 5 analysts giving stock ratings to AQST in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for AQST in the last 3 months.
Highest
Current $3.61
$11.00 (+204.71%)
Average
$9.20 (+154.85%)
Lowest
$6.00 (+66.20%)
Analyst
Recommendation
Action
Price target
Projected
Date
Roanna Ruiz
Leerink Partners
Buy
Reiterated
$11.00
+204.7%
11/05/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
$9.00
+149.3%
11/05/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$10.00
+177%
10/16/2026
Francois Brisebois
LifeSci Capital
Buy
Reiterated
$10.00
+177%
09/17/2026
Thomas Flaten
Lake Street
Buy
Maintained
$6.00
+66.2%
09/17/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$11.00
+204.7%
06/25/2026
Andreas Argyrides
Chardan Capital
Buy
Reiterated
$8.00
+121.6%
06/25/2026
David Amsellem
Piper Sandler
Buy
Reiterated
$8.00
+121.6%
05/15/2026
James Molloy
Alliance Global Partners
Buy
Maintained
$9.00
+149.3%
05/14/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
13.02M
14.45M
13.82M
7.56M
Cost of goods sold
5.84M
3.47M
4.02M
3.61M
Cost of revenue
5.84M
3.47M
4.02M
3.61M
Research and development expenses
3.20M
4.20M
3.96M
4.25M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
32.82M
10.98M
14.06M
14.17M
Operating expense
36.02M
15.18M
18.02M
18.42M
Total operating expenses
41.85M
18.65M
22.04M
22.03M
Operating income
-28.84M
-4.20M
-8.22M
-14.47M
Other non operating income
-
-
-
-
EBT including unusual items
-31.86M
-8.06M
-22.86M
-16.50M
EBT excluding unusual items
-31.86M
-8.06M
-11.18M
-16.50M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-31.86M
-8.06M
-22.86M
-16.50M
Net profit margin
-244.79%
-55.77%
-165.45%
-218.29%
Earnings per share
-0.14
-0.05
-0.07
-0.11
Interest and investment income
1.25M
83.00K
882.00K
853.00K
Interest expense
-4.27M
-3.94M
-3.84M
-2.88M
Net interest expenses
-3.02M
-3.85M
-2.96M
-2.03M
Depreciation and amortization charges
-
-
-
-
EBITDA
-28.68M
-4.09M
-8.09M
-14.31M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps